Clene CLNN 深 滬
等待開盤 09-23 09:30:00 美东时间
4.38
-0.160
-3.52%
華盛通- 最 高4.6995
- 今 開4.51
- 成交量 13.58万股
- 最 低 4.27
- 昨 收 4.54
- 總市值 6161.80万
- 52周最高 13.50
- 市盈率 靜 --
- 換手率 0.97%
- 52周最低 3.25
- 委 比 -0.68%
- 總股本 1406.80万
- 歷史最高 356.40
- 量 比 0.58
- 振 幅 9.46%
- 歷史最低 2.2801
- 每 手 1
- 風險率 1.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Clene announces insider-led $4 million financing round
An update from Clene ( ($CLNN) ) is now available. On September 15, 2026, Clene...
09-17 05:27
Clene Prices Registered Direct Offering Of 1,219,513 Shares At $3.28/Shr To Existing Shareholders With Total Gross Proceeds Of $4M
Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders $4 million registered direct offering priced at market under Nasdaq rules Proceeds are expected to be sufficient to f...
09-15 21:01
Clene Announces $4 Million Registered Direct Offering
Clene Inc. (Nasdaq: CLNN) completed a $4 million registered direct offering, with shares priced at $3.28, to existing shareholders, including insiders. The offering, led by Clene’s Chairman David Matlin and founding investor Kensington Capital Holdings, is expected to close on September 17, 2026. Proceeds will fund operations through mid-first quarter 2027, supporting regulatory efforts and commercialization for CNM-Au8, a therapy targeting neuro...
09-15 13:00
Clene to Present at Upcoming September Investor Conferences
Clene Inc. announced that its management will present at the 2026 Cantor Global Healthcare Conference on September 9, 2026, and at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, both in New York. The company will host 1x1 investor meetings at both events. Clene, a biopharmaceutical company focused on mitochondrial health and neurodegenerative diseases, will provide webcasts of the presentations on its website.
09-03 12:00
Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval
Clene Inc. announced new analyses showing that CNM-Au8-treated ALS patients with stabilized or decreased neurofilament light chain (NfL) levels had significantly longer survival and better functional outcomes compared to controls. These findings address FDA questions and aim to support accelerated approval. NfL, a biomarker of nerve cell injury, was found to correlate with clinical benefits, including slower disease progression and improved daily...
08-10 12:00
加州富豪开始数百公里的迁徙，原因竟是这个
①美国加州拟征财富税，推动不少亿万富豪涌入内华达州太浩湖旁的因克莱恩村和水晶湾； ②太浩湖北岸因历史划界脱离加州税管，富豪们于此地居住可实现税务与生活的双重套利； ③该征税提案引发多方反对，但超级富豪们仍加速转移资产与居所。
06-10 17:31
Clene Q1 GAAP每股亏损0.69美元，营收仅1万美元
临床阶段生物制药公司Clene周四公布2026年第一季度财报。公司GAAP每股亏损0.69美元，营收仅1万美元，远低于市场预期。不过，公司在ALS药物CN...
05-14 22:45
Clene Q1 EPS $(0.69) Misses $(0.66) Estimate, Sales $15.000K Miss $35.064K Estimate
Clene (NASDAQ:CLNN) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.66) by 4.55 percent. This is a 666.67 percent decrease over losses of $(0.09) per share from the same
05-14 20:39
Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
Clene Inc. announced its Q1 2026 financial results and updates on its CNM-Au8 programs for treating neurodegenerative diseases like ALS and MS. The company successfully completed an FDA Type C meeting and plans to submit an NDA under the accelerated approval pathway in Q3 2026. Clene also completed multiple financings totaling over $35 million and amended its debt facility to extend maturity. Despite a net loss of $8.1 million, the company expect...
05-14 12:00
